The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000

Philip J. Turner, J. M. Greenhalgh, H. Kurt, H. Eraksoy, R. Ozturk, A. Basustaoglu, V. Korten, S. Unal, S. Ulusoy, A. Yuce, Y. Taoova, J. Verhaegen, G. Verschraegen, P. de Mol, G. Glupczynski, M. Delmee, S. Lauwers, M. Struelens, R. Masterton, J. HoodA. Bint, P. Chadwick, R. Holliman, U. Riley, R. A. Swann, E. Priztbuer, R. Thomssen, A. Rodloff, J. Heesemann, H. Hahn, K. P. Schaal, E. Giacobone, R. Fontana, B. Markova, E. Chemelerova, D. Dzierzanowska, S. V. Resvan, P. Larsson, J. Bille

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated rom serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. Iwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.

Original languageEnglish
Pages (from-to)563-567
Number of pages5
JournalClinical Microbiology and Infection
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

meropenem
Acinetobacter
Imipenem
Tobramycin
Carbapenems
Ceftazidime
Ciprofloxacin
Infection

Keywords

  • Acinetobacter
  • Antibiotics
  • Carbapenems
  • Meropenem
  • MYSTIC

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. / Turner, Philip J.; Greenhalgh, J. M.; Kurt, H.; Eraksoy, H.; Ozturk, R.; Basustaoglu, A.; Korten, V.; Unal, S.; Ulusoy, S.; Yuce, A.; Taoova, Y.; Verhaegen, J.; Verschraegen, G.; de Mol, P.; Glupczynski, G.; Delmee, M.; Lauwers, S.; Struelens, M.; Masterton, R.; Hood, J.; Bint, A.; Chadwick, P.; Holliman, R.; Riley, U.; Swann, R. A.; Priztbuer, E.; Thomssen, R.; Rodloff, A.; Heesemann, J.; Hahn, H.; Schaal, K. P.; Giacobone, E.; Fontana, R.; Markova, B.; Chemelerova, E.; Dzierzanowska, D.; Resvan, S. V.; Larsson, P.; Bille, J.

In: Clinical Microbiology and Infection, Vol. 9, No. 6, 01.06.2003, p. 563-567.

Research output: Contribution to journalArticle

Turner, PJ, Greenhalgh, JM, Kurt, H, Eraksoy, H, Ozturk, R, Basustaoglu, A, Korten, V, Unal, S, Ulusoy, S, Yuce, A, Taoova, Y, Verhaegen, J, Verschraegen, G, de Mol, P, Glupczynski, G, Delmee, M, Lauwers, S, Struelens, M, Masterton, R, Hood, J, Bint, A, Chadwick, P, Holliman, R, Riley, U, Swann, RA, Priztbuer, E, Thomssen, R, Rodloff, A, Heesemann, J, Hahn, H, Schaal, KP, Giacobone, E, Fontana, R, Markova, B, Chemelerova, E, Dzierzanowska, D, Resvan, SV, Larsson, P & Bille, J 2003, 'The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000', Clinical Microbiology and Infection, vol. 9, no. 6, pp. 563-567. https://doi.org/10.1046/j.1469-0691.2003.00591.x
Turner, Philip J. ; Greenhalgh, J. M. ; Kurt, H. ; Eraksoy, H. ; Ozturk, R. ; Basustaoglu, A. ; Korten, V. ; Unal, S. ; Ulusoy, S. ; Yuce, A. ; Taoova, Y. ; Verhaegen, J. ; Verschraegen, G. ; de Mol, P. ; Glupczynski, G. ; Delmee, M. ; Lauwers, S. ; Struelens, M. ; Masterton, R. ; Hood, J. ; Bint, A. ; Chadwick, P. ; Holliman, R. ; Riley, U. ; Swann, R. A. ; Priztbuer, E. ; Thomssen, R. ; Rodloff, A. ; Heesemann, J. ; Hahn, H. ; Schaal, K. P. ; Giacobone, E. ; Fontana, R. ; Markova, B. ; Chemelerova, E. ; Dzierzanowska, D. ; Resvan, S. V. ; Larsson, P. ; Bille, J. / The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. In: Clinical Microbiology and Infection. 2003 ; Vol. 9, No. 6. pp. 563-567.
@article{f540d63fd8ef4ddeb24b9f196a5c7c9f,
title = "The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000",
abstract = "In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated rom serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. Iwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14{\%}, meropenem; 16{\%}, imipenem; 39{\%}, piperacillin-tazobactam; 41{\%}, tobramycin; 45{\%}, ceftazidime; and 53{\%}, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.",
keywords = "Acinetobacter, Antibiotics, Carbapenems, Meropenem, MYSTIC",
author = "Turner, {Philip J.} and Greenhalgh, {J. M.} and H. Kurt and H. Eraksoy and R. Ozturk and A. Basustaoglu and V. Korten and S. Unal and S. Ulusoy and A. Yuce and Y. Taoova and J. Verhaegen and G. Verschraegen and {de Mol}, P. and G. Glupczynski and M. Delmee and S. Lauwers and M. Struelens and R. Masterton and J. Hood and A. Bint and P. Chadwick and R. Holliman and U. Riley and Swann, {R. A.} and E. Priztbuer and R. Thomssen and A. Rodloff and J. Heesemann and H. Hahn and Schaal, {K. P.} and E. Giacobone and R. Fontana and B. Markova and E. Chemelerova and D. Dzierzanowska and Resvan, {S. V.} and P. Larsson and J. Bille",
year = "2003",
month = "6",
day = "1",
doi = "10.1046/j.1469-0691.2003.00591.x",
language = "English",
volume = "9",
pages = "563--567",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000

AU - Turner, Philip J.

AU - Greenhalgh, J. M.

AU - Kurt, H.

AU - Eraksoy, H.

AU - Ozturk, R.

AU - Basustaoglu, A.

AU - Korten, V.

AU - Unal, S.

AU - Ulusoy, S.

AU - Yuce, A.

AU - Taoova, Y.

AU - Verhaegen, J.

AU - Verschraegen, G.

AU - de Mol, P.

AU - Glupczynski, G.

AU - Delmee, M.

AU - Lauwers, S.

AU - Struelens, M.

AU - Masterton, R.

AU - Hood, J.

AU - Bint, A.

AU - Chadwick, P.

AU - Holliman, R.

AU - Riley, U.

AU - Swann, R. A.

AU - Priztbuer, E.

AU - Thomssen, R.

AU - Rodloff, A.

AU - Heesemann, J.

AU - Hahn, H.

AU - Schaal, K. P.

AU - Giacobone, E.

AU - Fontana, R.

AU - Markova, B.

AU - Chemelerova, E.

AU - Dzierzanowska, D.

AU - Resvan, S. V.

AU - Larsson, P.

AU - Bille, J.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated rom serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. Iwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.

AB - In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated rom serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. Iwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.

KW - Acinetobacter

KW - Antibiotics

KW - Carbapenems

KW - Meropenem

KW - MYSTIC

UR - http://www.scopus.com/inward/record.url?scp=0037626394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037626394&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2003.00591.x

DO - 10.1046/j.1469-0691.2003.00591.x

M3 - Article

C2 - 12848736

AN - SCOPUS:0037626394

VL - 9

SP - 563

EP - 567

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 6

ER -